Express Mail No.: EL862267408US Date of D posit: December 3, 2001

Please type a plus sign (+) in this box +

	F10/38(12-9/)
	Approved for use through 9/30/00. OMB 0651-0031
	Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to	a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO	Application Number	09/865,812 10/613,105
	Filing Date	05/25/01
INFORMATION DISCLOSURE	First Named Inventor	Rastelli
STATEMENT BY APPLICANT	Group Art Unit	1632
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	21402-018 (Cura-318)

9		10.54			LES PATENT DOCUMENTS TO THE PERSON			
Exan Initia			U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
17	// A1		5,871,697	02/16/99	Rothberg et al.			10/24/95

			FÖREGNEATENT DOCUMENTS		
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	81				

1				COTHER PRIOR ART ENONIPATENT LIBERATURE DOCUMENTS SELECTION
	Exa		Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
9	7		, C1	Capecchi, M. (1989). "Altering the genome by homologous recombination." Science 244: 1288-1292.
		P	C2	Heinzel, R. et al. (1986). "Molecular cloning and expression of cDNA for human antileukoprotease from cervix uterus." Eur. J. Biochem. 160(1): 61-67. GenBank Accession Number: X04470
	J		СЗ	Shimkets, R. et al. (1999). "Gene expression analysis by transcript profiling coupled to a gene database query." <i>Nat Biotechnol</i> <u>17(8)</u> : 798-803.

^{*} A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, ___, filed _ _, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

	<u> </u>		1	4
Examiner Signature		Date Considered	2/1	5/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1601217v1

Express Mail N .: EV109727221US Dat of Deposit: April 30, 2003

Please type a plus sign (+) in this box +



Modified Form 1449/PTO	Application Number	09/865,812 /6/6/3,8/2
	Filing Date	05/25/01
INFORMATION DISCLOSURE	First Named Inventor	Rastelli
STATEMENT BY APPLICANT	Group Art Unit	1635
	Examiner Name	Lacourciere, Karen A.
(use as many sheets as necessary)	Attorney Docket Number	21402-018 (Cura-318)

				U.S. PATENTI DOCUMENTS			
tials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
12	A2	5,633,227	05/27/1997	Muller, et al.			09/12/1994
J	АЗ	4,980,281	12/25/1990	Housey			02/10/1988

	- un.	And the second of the second o	and the state of t		
Exam Initials	Cite Foreign Patent Document No. Office Number		I rang of ratelites(s) of Applicant(s)	Date of Publication	Translation Yes No
	В				

94.2		DOTHER PRIORIANT NONPATENT/LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
Z	C4	Abe, et al. (1997). "Bacteria pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung." American Journal of Respiratory and Association. 156: 1235-1240.
1	C5	Bingle, et al. (1996). "Secretory leukoprotease inhibitor: partnering alpha1-proteinsase inhibitor to combat pulmonary inflammation." Thorax. 51(12): 1273-1274.
	C6	EMBASE Online Accesion No.: P03973 . 10/23/1986.
	,C7	EMBASE Online Accesion No.: X04470. 03/09/1987.
	C8	Fath, et al. (1998). "Interaction of secretory leukocyte protease inhibitor with heparin inhibits protease involved in asthma." Journal of Biological Chemistry. 273(22): 13563-13569.
	C9	Gipson, et al. (1999). "Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury." Journal of Immunology. 162(6): 3653-3662.
	C10	Kida, et al. (1992). "Serum secretory leukoprotease inhibitor levels to diagnose pneumonia in the elderly." The American Review of Respiratory Disease. 146(6): 1426-1429.
	C11	Thompson, et al. (1986). "Isolation properties, and complete amino acid sequence of human secretory leukocyte protease inhibitor, a potent inhibitor of leukocyte elastase." Proceedings of The National Academy of Sciences of USA. 83: 6692-6696.
	C12	Van Wetering, et al. (2000). "Regulation of SLPI and elafin release from bronchial epithelial cells by neutrophil defensins." American Journal of Physiology. 278(1): L51-L58.
	C13	Vogelmeier, et al. (1996). "Use of secretory leukoprotease inhibitor to augment lung antineutriphil elastase activity." Chest. 110(6): 261S-266S.
	C14	Wright, et al. (1999). "Secretory leukocyte protease inhibitor prevents allergen-induced pulmonary responses in animal models of asthma." The Journal of Pharmacology and Exerimental Therapeutics. 289(2): 1007-1014.
	<i>Q</i> 15	Partial International Search Report for PCT/US01/17211. Mailed February 26, 2003.

Express Mail N .: EV109727221US Dat of Dep sit: April 30, 2003

Page 2 of 2

* A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature Date Considered 7/15/06

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

TRA 1786036v1